View Financial HealthWaverley Pharma 배당 및 자사주 매입배당 기준 점검 0/6Waverley Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.공시 • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, CanadaBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg CanadaBoard Change • Apr 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.공시 • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.공시 • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.공시 • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.Board Change • Sep 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Jun 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.Reported Earnings • May 28First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (in line with 1Q 2022). Revenue: CA$118.7k (down 61% from 1Q 2022). Net loss: CA$339.6k (loss widened 9.2% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • May 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 29Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0 (up from CA$0.003 loss in 2Q 2021). Revenue: CA$421.8k (down 22% from 2Q 2021). Net loss: CA$24.0k (loss narrowed 84% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Board Change • Aug 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • May 01Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)Full year 2021 results: CA$0.015 loss per share (down from CA$0.013 loss in FY 2020). Revenue: CA$1.75m (up 28% from FY 2020). Net loss: CA$796.5k (loss widened 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 13Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022.Reported Earnings • Aug 27Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$543.4k (up 111% from 2Q 2020). Net loss: CA$147.4k (loss narrowed 27% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • May 27First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$1.38m (up 19% from FY 2019). Net loss: CA$705.8k (loss narrowed 42% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.공시 • Nov 13Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United StatesWaverley Pharma Inc. announce that the Company has obtained tentative approval of its Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection, 100 mg and 500 mg (formerly known as "WAV-101") in the United States (US). The tentative ANDA approval indicates that the technical requirements for approval have been met but approval can not be made effective or marketing begin until the patent on the reference listed drug has expired, which is projected to occur in 2022.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 WAVE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: WAVE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Waverley Pharma 배당 수익률 vs 시장WAVE의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (WAVE)n/a시장 하위 25% (CA)1.7%시장 상위 25% (CA)5.4%업계 평균 (Biotechs)2.4%분석가 예측 (WAVE) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 WAVE 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 WAVE 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 WAVE 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: WAVE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/05 19:17종가2026/05/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Waverley Pharma Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
공시 • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canada
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canada
Board Change • Apr 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
공시 • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.
Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
공시 • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.
Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.
Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
공시 • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.
Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.
Board Change • Sep 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Jun 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.
Reported Earnings • May 28First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (in line with 1Q 2022). Revenue: CA$118.7k (down 61% from 1Q 2022). Net loss: CA$339.6k (loss widened 9.2% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • May 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 29Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.
Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0 (up from CA$0.003 loss in 2Q 2021). Revenue: CA$421.8k (down 22% from 2Q 2021). Net loss: CA$24.0k (loss narrowed 84% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Board Change • Aug 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • May 01Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)Full year 2021 results: CA$0.015 loss per share (down from CA$0.013 loss in FY 2020). Revenue: CA$1.75m (up 28% from FY 2020). Net loss: CA$796.5k (loss widened 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 13Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022.
Reported Earnings • Aug 27Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$543.4k (up 111% from 2Q 2020). Net loss: CA$147.4k (loss narrowed 27% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • May 27First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$1.38m (up 19% from FY 2019). Net loss: CA$705.8k (loss narrowed 42% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
공시 • Nov 13Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United StatesWaverley Pharma Inc. announce that the Company has obtained tentative approval of its Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection, 100 mg and 500 mg (formerly known as "WAV-101") in the United States (US). The tentative ANDA approval indicates that the technical requirements for approval have been met but approval can not be made effective or marketing begin until the patent on the reference listed drug has expired, which is projected to occur in 2022.